ASH 2020 | Venetoclax plus azacitidine in FLT3-mutated AML
Marina Konopleva, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX shares the results of an analysis of venetoclax (Ven) and azacitidine (Aza) therapy in treatment-naïve FLT3-mutated acute myeloid leukemia (AML) patients who are unfit for intensive treatment. The median overall survival was 13.3 months for Ven+Aza, compared to 8.6 months for Aza patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consultancy (includes expert testimony): AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, Kisoji
Equity ownership: Stocks, Reata Pharmaceuticals
Research funding: AbbVie, Genentech, F. Hoffman La-Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage, Astra Zeneca
Patents and royalties: Reata Pharmaceuticals
